Than G, Seppälä M, Julkunen M, Szabo D, Bodis J, Szilagyi A, Csaba I
Department of Obstetrics and Gynaecology, Medical School, Pécs, Hungary.
Hum Reprod. 1987 Oct;2(7):549-51. doi: 10.1093/oxfordjournals.humrep.a136587.
Twenty-four women, 11 with endometriosis and 13 with fibrocystic mastopathy, were treated with a medium dose (300-400 mg daily) of Danazol for 6 months. The circulating level of progesterone, the 34K insulin-like growth factor-binding protein (IGF-bp) and endometrial protein PP14 (placental protein 14) were measured by specific radioimmunoassays before and during treatment. The serum progesterone concentration decreased significantly during Danazol treatment, as did the serum levels of 34K IGF-bp and PP14. By the third month of therapy amenorrhoea was observed in 22 out of 24 women and this was accompanied by a further decline in the IGF-bp and PP14 levels. In light of the previous observations on the IGF-bp and PP14 synthesis by secretory endometrium and the fact that Danazol causes endometrial atrophy, these results suggest that Danazol treatment has an effect on endometrial protein secretion.
24名女性，其中11名患有子宫内膜异位症，13名患有纤维囊性乳腺病，接受了为期6个月的中等剂量（每日300 - 400毫克）达那唑治疗。在治疗前和治疗期间，通过特定的放射免疫测定法测量了孕酮的循环水平、34K胰岛素样生长因子结合蛋白（IGF - bp）和子宫内膜蛋白PP14（胎盘蛋白14）。在达那唑治疗期间，血清孕酮浓度显著降低，34K IGF - bp和PP14的血清水平也显著降低。到治疗第三个月时，24名女性中有22名出现闭经，同时IGF - bp和PP14水平进一步下降。鉴于之前关于分泌期子宫内膜合成IGF - bp和PP14的观察结果以及达那唑会导致子宫内膜萎缩这一事实，这些结果表明达那唑治疗对子宫内膜蛋白分泌有影响。
